Antonopoulos Michael, Bonios Michael J, Dimopoulos Stavros, Leontiadis Evangelos, Gouziouta Aggeliki, Kogerakis Nektarios, Koliopoulou Antigone, Elaiopoulos Dimitris, Vlahodimitris Ioannis, Chronaki Maria, Chamogeorgakis Themistocles, Drakos Stavros G, Adamopoulos Stamatis
Heart Failure, Transplant and Mechanical Circulatory Support Units, Onassis Cardiac Surgery Center, 17674 Athens, Greece.
Cardiac Surgery Intensive Care Unit, Onassis Cardiac Surgery Center, 17674 Athens, Greece.
J Cardiovasc Dev Dis. 2024 Feb 16;11(2):61. doi: 10.3390/jcdd11020061.
Heart Failure is a chronic and progressively deteriorating syndrome that has reached epidemic proportions worldwide. Improved outcomes have been achieved with novel drugs and devices. However, the number of patients refractory to conventional medical therapy is growing. These advanced heart failure patients suffer from severe symptoms and frequent hospitalizations and have a dismal prognosis, with a significant socioeconomic burden in health care systems. Patients in this group may be eligible for advanced heart failure therapies, including heart transplantation and chronic mechanical circulatory support with left ventricular assist devices (LVADs). Heart transplantation remains the treatment of choice for eligible candidates, but the number of transplants worldwide has reached a plateau and is limited by the shortage of donor organs and prolonged wait times. Therefore, LVADs have emerged as an effective and durable form of therapy, and they are currently being used as a bridge to heart transplant, destination lifetime therapy, and cardiac recovery in selected patients. Although this field is evolving rapidly, LVADs are not free of complications, making appropriate patient selection and management by experienced centers imperative for successful therapy. Here, we review current LVAD technology, indications for durable MCS therapy, and strategies for timely referral to advanced heart failure centers before irreversible end-organ abnormalities.
心力衰竭是一种慢性且逐渐恶化的综合征,在全球范围内已达到流行程度。新型药物和设备已使治疗效果有所改善。然而,对传统药物治疗无效的患者数量正在增加。这些晚期心力衰竭患者症状严重,频繁住院,预后不佳,给医疗保健系统带来了巨大的社会经济负担。该组患者可能适合接受晚期心力衰竭治疗,包括心脏移植和使用左心室辅助装置(LVAD)进行慢性机械循环支持。心脏移植仍然是符合条件的候选人的首选治疗方法,但全球范围内的移植数量已达到平稳状态,且受到供体器官短缺和等待时间延长的限制。因此,LVAD已成为一种有效且持久的治疗形式,目前正被用作心脏移植的桥梁、终生存治疗以及特定患者的心脏恢复治疗。尽管该领域发展迅速,但LVAD并非没有并发症,因此由经验丰富的中心进行适当的患者选择和管理对于成功治疗至关重要。在此,我们回顾当前的LVAD技术、持久机械循环支持治疗的适应症以及在不可逆的终末器官异常出现之前及时转诊至晚期心力衰竭中心的策略。